CG Oncology (CGON) Operating Income (2023 - 2026)

CG Oncology (CGON) has 4 years of Operating Income data on file, last reported at -$66.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income fell 57.3% year-over-year to -$66.4 million; the trailing twelve-month figure through Mar 2026 stood at -$215.0 million (down 59.94% YoY), and the FY2025 full-year result was -$190.8 million, down 66.37% from the prior year.
• Operating Income for Q1 2026 stood at -$66.4 million, down from -$48.7 million in the prior quarter.
• Across five years, Operating Income topped out at -$9.7 million in Q1 2023 and bottomed at -$66.4 million in Q1 2026.
• The 4-year median for Operating Income is -$28.3 million (2024), against an average of -$32.9 million.
• The widest annual swing landed in 2024, when Operating Income sank 131.14%; it then dropped 27.99% in 2025.
• A 4-year view of Operating Income shows it stood at -$19.4 million in 2023, then tumbled by 96.58% to -$38.0 million in 2024, then declined by 27.99% to -$48.7 million in 2025, then slumped by 36.32% to -$66.4 million in 2026.
• The last three Operating Income figures came in at -$66.4 million (Q1 2026), -$48.7 million (Q4 2025), and -$51.1 million (Q3 2025), per Business Quant data.

Peer Comparison